Literature DB >> 15871288

[Immunohistochemistry study of EGFR expression in head and neck squamous cell carcinoma].

X Altuna Mariezkurrena1, J Algaba Guimerá, J Wang Rodríguez, R Weisman, W Ongkeko.   

Abstract

EGFR is an important transmembrane receptor member of the family of tyrosine kinases, that translates signals from both outside and inside the cell and plays a key role in numerous proceses that affect tumour development, growth, progresion, differentiation, inhibition of apoptosis and metastasis. Immunohistochemistry studies have shown that 40-80% of head and neck squamous cell carcinomas express EGFR and it has been suggested as a potential independent prognostic parameter. The objective of this study is to evaluate by immunohistochemistry the expresi6n of EGFR in a series of Head and Neck Squamous Cell Carcinoma and correlate it to clinico-pathological features and prognostic significance. We investigated expression of EGFR in 44 samples. There was a high expression in 41% of the cases. Even if we have not found that the expression of EGFR correlated with the prognosis of these patients the presence of EGFR is very important because there are chemical agents or drugs that can inhibit its activity.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15871288     DOI: 10.1016/s0001-6519(05)78589-7

Source DB:  PubMed          Journal:  Acta Otorrinolaringol Esp        ISSN: 0001-6519


  2 in total

1.  Evaluation of epidermal growth factor receptor expression by a new scoring system in head-and-neck squamous cell carcinoma and its association with various pathological prognostic factors.

Authors:  Jyoti Verma; Vishal Dhingra; Sapan Srivastava; Vatsala Misra; Kachnar Varma; Shilpy Singh
Journal:  J Oral Maxillofac Pathol       Date:  2018 Jan-Apr

2.  Expression of epidermal growth factor receptor in oral and esophageal squamous-cell carcinoma.

Authors:  Fatemeh Shahsavari; Rosa Miri; Maedeh Ghorbanpour
Journal:  Dent Res J (Isfahan)       Date:  2020-03-17
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.